Atezolizumab with carboplatin or cisplatin and pemetrexed for untreated advanced non-squamous non-small-cell lung cancer ID1495
In development [GID-TA10395] Expected publication date: TBC
Search results
592 results
-
-
Durvalumab with chemotherapy for untreated advanced non-small-cell lung cancer with no EGFR or ALK mutations [ID3751]
In development [GID-TA10616] Expected publication date: TBC
-
Durvalumab for treating recurrent or metastatic squamous cell head and neck cancer [ID3752]
In development [GID-TA10617] Expected publication date: TBC
-
Inebilizumab for treating neuromyelitis optica spectrum disorders [ID1529]
In development [GID-TA10522] Expected publication date: TBC
-
Elotuzumab for multiple myeloma [ID966]
In development [GID-TA10134] Expected publication date: TBC
-
Pembrolizumab for previously treated advanced hepatocellular carcinoma [ID1458]
In development [GID-TA10380] Expected publication date: TBC
-
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (review of HST3) ID1642
In development [GID-TA10642] Expected publication date: TBC
-
Idasanutlin with cytarabine for treating relapsed or refractory acute myeloid leukaemia [ID1597]
In development [GID-TA10494] Expected publication date: TBC
-
Lenalidomide with R-CHOP for untreated activated diffuse large B-cell lymphoma [ID1611]
In development [GID-TA10480] Expected publication date: TBC
-
Nivolumab for maintenance treatment of extensive stage small-cell lung cancer after chemotherapy ID1264
In development [GID-TA10365] Expected publication date: TBC
-
Nivolumab for small-cell lung cancer after platinum-based chemotherapy [ID1126]
In development [GID-TA10158] Expected publication date: TBC
-
Ibrutinib with obinutuzumab for untreated chronic lymphocytic leukaemia and small lymphocytic lymphoma (ID1375)
In development [GID-TA10360] Expected publication date: TBC
-
Ticagrelor for preventing cardiovascular events in people with type 2 diabetes and coronary artery disease [ID1514]
In development [GID-TA10429] Expected publication date: TBC
-
Pembrolizumab for previously treated metastatic triple negative breast cancer [ID1246]
In development [GID-TA10295] Expected publication date: TBC
-
Lumacaftor with ivacaftor for treating cystic fibrosis in children aged 2 to 11 years old homozygous for the F508del mutation [ID1486]
In development [GID-TA10390] Expected publication date: TBC
-
Atezolizumab in combination for untreated squamous non-small-cell lung cancer [ID1481]
In development [GID-TA10546] Expected publication date: TBC
-
Durvalumab for untreated EGFR-negative, ALK-negative non-small-cell lung cancer ID1331
In development [GID-TA10318] Expected publication date: TBC
-
Vocimagene amiretrorepvec with extended-release 5-fluorocytosine for treating recurrent high-grade glioma [ID1425]
In development [GID-TA10542] Expected publication date: TBC
-
Nivolumab for untreated advanced hepatocellular carcinoma [ID1248]
In development [GID-TA10221] Expected publication date: TBC
-
Entinostat for treating hormone receptor-positive breast cancer after hormonal therapy ID1260
In development [GID-TA10309] Expected publication date: TBC
-
Ibrutinib for untreated mantle cell lymphoma (ID1221)
In development [GID-TA10185] Expected publication date: TBC
-
KTE-C19 for previously treated B-precursor acute lymphoblastic leukaemia in people aged 2 to 21 ID1336
In development [GID-TA10316] Expected publication date: TBC
-
The MAGEC system for spinal lengthening in children with scoliosis
In development [GID-MT544] Expected publication date: 15 September 2020
-
Nitisinone for treating alkaptonuria [ID2691]
In development [GID-TA10659] Expected publication date: TBC
-
Mental health community settings
In development [GID-SGWAVE0702] Expected publication date: TBC
-
Stye: antimicrobial prescribing
In development [GID-NG10167] Expected publication date: TBC
-
Blepharitis: antimicrobial prescribing
In development [GID-NG10168] Expected publication date: TBC
-
Durvalumab for untreated PD-L1 positive metastatic urothelial bladder cancer ID1169
In development [GID-TA10324] Expected publication date: TBC
-
Durvalumab with tremelimumab for untreated PD-L1-positive urothelial bladder cancer ID1335
In development [GID-TA10315] Expected publication date: TBC
-
Olaparib for maintenance treatment of BRCA mutation-positive metastatic pancreatic cancer after initial platinum-based chemotherapy [ID1518]
In development [GID-TA10504] Expected publication date: TBC
-
Trastuzumab deruxtecan for treating HER2-positive unresectable or metastatic breast cancer after 2 or more anti-HER2 therapies [ID2697]
In development [GID-TA10582] Expected publication date: 19 May 2021
-
Pembrolizumab with chemotherapy for untreated metastatic urothelial cancer ID1545
In development [GID-TA10418] Expected publication date: TBC
-
Nivolumab with ipilimumab for untreated unresectable metastatic oesophageal squamous cell carcinoma [ID1629]
In development [GID-TA10576] Expected publication date: TBC
-
Epilepsies in adults: diagnosis and management update (Please see Epilepsies in children, young people and adults)
In development [GID-NG10110] Expected publication date: TBC
-
Epilepsies in children, young people and adults
In development [GID-NG10112] Expected publication date: 16 November 2021
-
Onasemnogene abeparvovec for treating spinal muscular atrophy type 1 [ID1473]
In development [GID-HST10026] Expected publication date: 25 March 2021
-
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapy [ID1536]
In development [GID-TA10466] Expected publication date: 28 April 2021
-
Ravulizumab for treating atypical haemolytic uraemic syndrome (aHUS) [ID1530]
In development [GID-TA10564] Expected publication date: TBC
-
Quizartinib for treating relapsed or refractory acute myeloid leukaemia [ID1325]
In development [GID-TA10363] Expected publication date: TBC
-
Pexidartinib for treating symptomatic tenosynovial giant cell tumour [ID1682]
In development [GID-TA10609] Expected publication date: TBC
-
Sapropterin for treating phenylketonuria [ID1475]
In development [GID-TA10378] Expected publication date: 21 April 2021
-
Elosulfase alfa for treating mucopolysaccharidosis type IVa (review of HST2) [ID1643]
In development [GID-HST10027] Expected publication date: TBC
-
Venetoclax with a hypomethylating agent or low dose cytarabine for untreated acute myeloid leukaemia when intensive chemotherapy is unsuitable [ID1564]
In development [GID-TA10478] Expected publication date: 22 September 2021
-
Dupilumab for treating severe asthma [ID1213]
In development [GID-TA10276] Expected publication date: TBC
-
Olaparib for maintenance treatment of recurrent, platinum-sensitive ovarian, fallopian tube and peritoneal cancer that has responded to platinum-based chemotherapy (CDF review of TA620) [ID3788]
In development [GID-TA10712] Expected publication date: TBC
-
Bempedoic acid for treating primary hypercholesterolaemia or mixed dyslipidaemia [ID1515]
In development [GID-TA10534] Expected publication date: TBC
-
Acalabrutinib for untreated and treated chronic lymphocytic leukaemia [ID1613]
In development [GID-TA10532] Expected publication date: TBC
-
Roxadustat for treating anaemia in people with chronic kidney disease [ID1483]
In development [GID-TA10610] Expected publication date: 02 March 2022
-
Tafasitamab with lenalidomide for treating relapsed or refractory diffuse large B-cell lymphoma [ID3795]
In development [GID-TA10645] Expected publication date: 10 August 2022
-
Ticagrelor for preventing stroke after previous ischaemic stroke or high-risk transient ischaemic attack [ID2689]
In development [GID-TA10663] Expected publication date: 01 June 2022